Mari S Golub1, Casey E Hogrefe. 1. Department of Environmental Toxicology, University of California, Davis, One Shields Ave, Davis, CA, 95616, USA, msgolub@ucdavis.edu.
Abstract
RATIONALE: The selective serotonin reuptake inhibitor (SSRI) fluoxetine is the only psychopharmacological agent approved for use in children. While short-term studies of side effects have been performed, long-term consequences for brain development are not known. Such studies can be performed in appropriate animal models if doses modeling therapeutic use in children are known. OBJECTIVES: The goal of this study was to identify a daily dose of fluoxetine in juvenile monkeys which would result in serum fluoxetine and norfluoxetine concentrations in the therapeutic range for children. METHODS: Juvenile (2.5-year-old rhesus monkeys, n = 6) received single administration of doses of 1, 2, and 4 mg/kg day fluoxetine on a background of chronic dosing at an intermediate level to provide steady-state conditions to model therapeutic administration. Using nonlinear modeling, standard pharmacokinetic parameters were derived. Cerebrospinal fluid monoamine neurotransmitters were assayed to confirm the pharmacological effects. RESULTS: Dose-dependent area under the curve (AUC) and C max values were seen, while T max and absorption/elimination half-lives were minimally influenced by dose. A dosage of 2 mg/kg day given over a 14-week period led to steady-state serum concentrations of active agent (fluoxetine + norfluoxetine) similar to those recorded from drug monitoring studies in children. Cisternal cerebrospinal fluid concentrations of serotonin increased significantly over the 14-week period, while concentrations of the serotonin metabolite (5-HIAA) were lower but not significantly different. CONCLUSIONS: A dose of 2 mg/kg day fluoxetine in juvenile rhesus monkeys provides an internal dose similar to therapeutic use in children and will help establish a valuable animal model for understanding fluoxetine's therapeutic and potential adverse effects in children.
RATIONALE: The selective serotonin reuptake inhibitor (SSRI) fluoxetine is the only psychopharmacological agent approved for use in children. While short-term studies of side effects have been performed, long-term consequences for brain development are not known. Such studies can be performed in appropriate animal models if doses modeling therapeutic use in children are known. OBJECTIVES: The goal of this study was to identify a daily dose of fluoxetine in juvenile monkeys which would result in serum fluoxetine and norfluoxetine concentrations in the therapeutic range for children. METHODS: Juvenile (2.5-year-old rhesus monkeys, n = 6) received single administration of doses of 1, 2, and 4 mg/kg day fluoxetine on a background of chronic dosing at an intermediate level to provide steady-state conditions to model therapeutic administration. Using nonlinear modeling, standard pharmacokinetic parameters were derived. Cerebrospinal fluid monoamine neurotransmitters were assayed to confirm the pharmacological effects. RESULTS: Dose-dependent area under the curve (AUC) and C max values were seen, while T max and absorption/elimination half-lives were minimally influenced by dose. A dosage of 2 mg/kg day given over a 14-week period led to steady-state serum concentrations of active agent (fluoxetine + norfluoxetine) similar to those recorded from drug monitoring studies in children. Cisternal cerebrospinal fluid concentrations of serotonin increased significantly over the 14-week period, while concentrations of the serotonin metabolite (5-HIAA) were lower but not significantly different. CONCLUSIONS: A dose of 2 mg/kg day fluoxetine in juvenile rhesus monkeys provides an internal dose similar to therapeutic use in children and will help establish a valuable animal model for understanding fluoxetine's therapeutic and potential adverse effects in children.
Authors: Susanne Koch; Kenneth W Perry; David L Nelson; Richard G Conway; Penny G Threlkeld; Frank P Bymaster Journal: Neuropsychopharmacology Date: 2002-12 Impact factor: 7.853
Authors: Frank P Bymaster; Wei Zhang; Petra A Carter; Janice Shaw; Eyassu Chernet; Lee Phebus; David T Wong; Kenneth W Perry Journal: Psychopharmacology (Berl) Date: 2002-01-29 Impact factor: 4.530
Authors: George M Anderson; Allyson J Bennett; Katherine P Weld; Judy G Pushkas; David M Ocame; J Dee Higley Journal: Psychopharmacology (Berl) Date: 2002-03-01 Impact factor: 4.530
Authors: Shu-Yi Su; Casey E Hogrefe-Phi; John M Asara; Christoph W Turck; Mari S Golub Journal: Eur Neuropsychopharmacol Date: 2016-04-12 Impact factor: 4.600
Authors: Mari S Golub; Edward P Hackett; Casey E Hogrefe; Csaba Leranth; John D Elsworth; Robert H Roth Journal: Dev Cogn Neurosci Date: 2017-05-01 Impact factor: 6.464